HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hélène Sicard Selected Research

KIR3DL2 Receptors

9/2015A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.
10/2014Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hélène Sicard Research Topics

Disease

6Neoplasms (Cancer)
01/2017 - 05/2009
2Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
11/2014 - 10/2014
1Fever (Fevers)
10/2010
1Chills
10/2010
1Abdominal Pain (Pain, Abdominal)
10/2010
1Lymphoma (Lymphomas)
05/2009
1Tuberculosis (Tuberculoses)
02/2007

Drug/Important Bio-Agent (IBA)

2KIR3DL2 ReceptorsIBA
09/2015 - 10/2014
2AntigensIBA
12/2014 - 02/2007
2bromohydrin pyrophosphateIBA
10/2010 - 05/2009
1Biomarkers (Surrogate Marker)IBA
01/2017
1Tumor Biomarkers (Tumor Markers)IBA
10/2014
1Pharmaceutical PreparationsIBA
01/2013
1Interleukin-2 (IL2)IBA
10/2010
1Rituximab (Mabthera)FDA Link
05/2009
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
05/2009
1Peptides (Polypeptides)IBA
02/2007
1VaccinesIBA
02/2007

Therapy/Procedure

4Immunotherapy
09/2015 - 05/2009
2Therapeutics
11/2014 - 01/2013